Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LENA: Phase 3 Study of AKP-022 in Endometriosis
jRCT2031250206Phase 3Active, not recruiting
- Sponsor
- ASKA Pharmaceutical Holdings Co., Ltd.
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of relugolix + estradiol + norethindrone in endometriosis (3 arms), sponsored by ASKA Pharmaceutical Holdings Co., Ltd. Primary endpoint: Change from baseline in maximum VAS score for endometriotic pelvic pain from week 20 to week 24. Started Aug 2025; status: active, not recruiting.
02
Drugs
relugolix + estradiol + norethindrone
03
Conditions
endometriosis
Beyond the preview
Go deeper on jRCT2031250206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250206.